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Abstract
A novel polyrotaxane (PR)-based triblock copolymer was 
exploited as polymeric carrier for doxorubicin (DOX). A sam-
ple holding a feed molar ratio of Pluronic F127 to β-CD to 
poly(ethylene glycol) methyl ether methacrylate (PEGMA) 
equal to 1:30:20 was synthesized via the in situ atom trans-
fer radical polymerization (ATRP) and then conjugated with 
DOX using pH sensitive hydrazone linker. The resulting 
PR-DOX conjugates enabled to self-assemble into nano-par-
ticles of about 70 nm in diameter in aqueous solution as evi-
denced by TEM. The release of DOX was varied from 10 % to 
37 % over 72 h at physiological and acidic pH, respectively. The 
PR-based triblock copolymer without DOX conjugation showed 
almost non toxicity, while these nano-particles with DOX con-
jugation presented increased toxicity.
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1 Introduction
During the past decade there has been a growing interest 
in the investigation of polymeric conjugates or polymer-drug 
conjugates as potential drug delivery systems [1]. When poorly 
water- soluble drugs are covalently linked to water-soluble pol-
ymers or amphiphlic block copolymers to give rise to the poly-
meric conjugates, they generally enable to self-assemble into 
nano-sized polymeric micelles with a size of about 50-150 nm 
in diameter in aqueous solution. These micelles usually show a 
unique core-shell structure, a hydrophobic core surrounded by 
a hydrophilic outer shell [2], which can easily escape from the 
blood vessel and accumulate in tumor tissues‒a phenomenon 
known as “enhanced permeability and retention (EPR) effect” 
[3,4]. Consequently, these micelles can be passively targeted to 
tumor site with the modified pharmacokinetics at the body and 
cellular level.
An ideal drug-loaded nano-particle should be stable in both 
blood circulation and healthy tissues, but release free drug once 
it is internalized by the cancer cells. For a drug to be delivered 
at the target site in a controlled manner, the development of pH-
sensitive polymeric conjugates for cancer chemotherapy has re-
cently attracted tremendous attention due to the mildly acidic 
pH intrinsically encountered in tumor (pH=5) other than in the 
healthy tissues (pH=7.4) [5]. To this end, such acid-labile moie-
ties as cis-aconitic acid [6] and hydrazine [7] are extensively 
exploited in polymeric conjugate chemistry.
Cyclodextrins (CDs) constitute a series of cyclic oligosac-
charides composed of 6, 7 and 8 D-glucose units linked by 
α-1,4 linkage and are named as α-, β- and γ-CD, respectively. 
In addition to small molecules, they can include polymers to 
give access to polypseudoro-taxanes (PPRs) and polyrotaxanes 
(PRs) after end-capping with polymers or oligomers via the 
atom transfer free radical polymerization (ATRP) [8]. Since 
CDs are nontoxic and biodegradable, the CD-based PRs have 
been explored not only for fundamental supramolecular poly-
mer research [9], but also for polymer therapeutics [10]. On 
one hand, this is because there are a large number of hydroxyls 
on the CD rings which could be easily modified by chemical 
P periodica polytechnica
Chemical Engineering 
58/1(2014)55-60
doi:10.3311/PPch.7202
http://www.periodicapolytechnica.org/ch
Creative Commons Attribution b
research article
Lan Jiang
Ze-ming Gao
Lin Ye
Ai-ying Zhang
Zeng-guo Feng
School of Materials Science and Engineering, Beijing Institute of Technology,
Beijing 100081, China
e-mail: sainfeng@bit.edu.cn
56 Per. Pol. Chem. Eng. Lan Jiang / Ze-ming Gao / Lin Ye / Ai-ying Zhang / Zeng-guo Feng
reactions, thus allowing the conjugation of bioactive agent, for 
example, DOX as an anti-tumor drug to synthesize polymeric 
conjugates. On the other hand, as threaded CDs can freely slide 
and rotate along the included polymer chain, this configura-
tional flexibility is beneficial to the formation of polymeric mi-
celles via the self-aggregation of polymeric conjugates because 
the grafted bioactive agent on the CD rings is decoupled with 
the main chain restriction. Several investigations on CD-based 
PRs as drug nano-carriers were reported in the literature [11]. 
However, their releasing strategies were mostly focused on the 
dissociation of supramolecular structure via hydrolysis of the 
terminal bulky groups, which would lead to the release of the 
drug along with the CD slipping off the polymer main chain, 
other than the cleavage of the grafted drugs off the CD rings. 
The research on stimuli-triggered release of drug from the CD 
rings is still an unfinished task.
In this report, we prepared a pH-triggered target delivery 
system of DOX conjugated to β-CDs entrapped on the Pluronic 
F127 block of a PR-based triblock copolymer via acid-labile 
hydrazone linkage. The obtained PR-DOX conjugates were 
self-assembled into around 70 nm-diameter nano-particles in 
aqueous solution. The release behavior of DOX was evaluated 
at pH=7.4 and 5, respectively. The in vitro experiments toward 
Hela cells showed these nano-particles having lower cytotoxic-
ity than the free drug and enabling to efficiently transfer and 
release the drug into the cells.
2 Experimental part
2.1 Materials
N,N′-Carbonyldiimidazole (CDI) was purchased from Alfa 
Aesar, USA. Doxorubicin·HCl (DOX·HCl) was available from 
HuaFeng United Technology Co., Ltd, Beijing, China. Pluron-
ic F127 comprising a central block of 65 PPO units and two 
PEO blocks of 100 units (Mn=12600 Da), poly(ethylene gly-
col) methyl ether methacrylate (PEGMA) (Mn=1100 Da) and 
N,N,N’,N’’,N’’-pentamethyldiethylenetriamine (PMDETA) were
purchased from Sigma, USA. PEGMA was passed over a short 
basic alumina column to remove the inhibitor before polymeri-
zation. Copper(I) chloride (Cu(I)Cl) was prepared from CuCl2, 
purified by stirring in acetic acid, washed with methanol and 
finally dried under vacuum prior to use. All other solvents and 
reagents were of analytical grade.
2.2 Synthesis of PR-based block copolymer
As previously reported [12], selected PR-based triblock co-
polymer was synthesized via the in situ ATRP of poly(ethylene 
glycol) methyl ether methacrylate (PEGMA) initiated with a 
PPR comprising a distal 2-bromopropionyl end-capped Pluron-
ic F127 and β-CDs. The PR-based triblock copolymer was des-
ignated as F-30-20, where F means Pluronic F127, and 30 and 
20 are the feed molar ratios of β-CD and PEGMA to Pluronic 
F127, respectively. The found molar ratio of Pluronic F127 to 
β-CD to PEGMA was 1:21.4:93.1 as measured by 1H NMR. 
The number-average molecular weight was 4.47×105 Da and the 
polydispersity index was 1.07 as determined by GPC analysis.
2.3 Synthesis of polyrotaxane having amino pendant 
group (PR-HYZ)
As a typical sample, F-30-20 (200 mg, 1.44 μmol) was 
dissolved in 4 mL DMF and then mixed with CDI (74 mg, 
0.462 mmol) dissolved in 2 mL DMF. After stirring for 2 h at 
40 °C, the mixture was dropped into 80 % hydrazine hydrate 
(184 mg, 3.7 mmol) and continuously stirred at room tempera-
ture for 2 h. The mixture was dialyzed using a dialysis bag 
(MWCO 3500) for 24 h with water changing every 8 hours, 
and finally freeze-dried to give rise to the hydrazine containing 
polyrotaxane, yield 84.5 %.
2.4 Synthesis of PR-DOX
To conjugate DOX to β-CDs entrapped on the Pluronic 
F127 backbone of the PR-based triblock copolymer, PR-HYZ 
(100 mg, 0.724 μmol) was dissolved in 7 mL of DMSO, and 
the certain amount of DOX•HCl was added. The mixture was 
stirred at room temperature for 72 h under protection from light. 
The crude product was dialyzed using a dialysis bag (MWCO 
3500) for 24 h with water changing every 8 hours, followed by 
gel purification by using Sephadex LH-20 to completely re-
move unbound DOX using DMF as elution solvent to yield the 
PR-DOX conjugate (PR-DOX), yield 82.7 %.
2.5 Preparation of PR-DOX micelles
The PR-DOX micelles were prepared by directly dissolving 
the PR-DOX conjugate in water and allowing it to stand over-
night. The resulting solution was then diluted to the desired 
concentration with the proper amount of distilled water.
2.6 In vitro release of DOX from polymeric micelles
A release study was performed at 37 °C in a Guo Hua THZ82 
incubator shaker (Jiangsu, China). A dialysis bag (MWCO 
3500) containing 3 mL PR-DOX micelle solution was placed 
into a flask containing 60 mL 0.1 M citrate/phosphate buffers 
at pH=5 and 7.4, respectively. The flask was shaken at 100 rpm 
at 37±0.5 °C. At selected time intervals, 3 mL solution outside 
the dialysis bag was removed for UV-Vis analysis and replaced 
with the same amount of fresh buffered solution. The DOX 
concentration was determined based on the absorbance inten-
sity at 480 nm according to the standard line obtained from 
a series of solutions with different DOX concentrations. The 
release experiments were conducted in triplicate and take the 
arithmetic mean as the results.
2.7 Evaluation of in vitro cytotoxicity of PR-DOX
The cytotoxicity of the PR-DOX nano-particles against 
Hela cells (ATCC, USA) was assessed by using the 
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3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide 
(MTT) assay. Hela cells were seeded in 96-well plates and in-
cubated for 24 h. The media were replaced with fresh medium 
containing free DOX and PR-DOX micelles with certain DOX 
concentrations, and incubated in a humidified atmosphere con-
taining 5 % CO2 at 37 ºC for 48 h. Thereafter, MTT solution 
was added. The plates were incubated at 37 °C for another 4 h. 
The intracellular metabolized product formazan of MTT was 
retrieved by addition of DMSO. The plates were read at 550 nm 
(Biotek synergy2, USA), and the cell viability was calculated.
2.8 Characterization of the drug-conjugated 
polyrotaxanes
1H NMR (400 MHz) spectra were recorded on a Bruker 
ARX-400 spectrometer at room temperature using DMSO-d6 
as solvent and tetramethylsilane (TMS) as internal standard. 
UV-vis spectra were performed on a Hitachi U-2800 spectro-
photometer. Samples for trans-mission electron microscopy 
(TEM, Tecnai G220 S-TWIN, FEI, Netherlands) observation 
were prepared by dropping a few microliters of the aqueous so-
lution (0.5 mg/mL) of the sample on a copper grid coated with 
amorphous carbon. FTIR spectra were measured using Shi-
madzu IR Prestige-21 FTIR spectrometer at room temperature 
in the range between 4000 and 500 cm-1, with a resolution of 
2 cm-1 and 20 scans. Samples were prepared by dropping their 
corresponding chloroform solutions on KBr plate and drying at 
50 °C. Gel Permeation Chromatographic (GPC) measurements 
were carried out at 50 ºC on a Waters 2410 instrument using 
DMF and LiBr (0.05 M) as a mixing eluent at a flow rate of 1.0 
mL/min. All the GPC data were calibrated by using polystyrene 
(PS) standards.
3 Results and discussion
3.1 Synthesis and characterization of PR-DOX
According to our previous report [12 a], a PR-based tri-
block copolymer sample F-30-20 was synthesized via the in 
situ ATRP of PEGMA initiated with a PPR made from a dis-
tal 2-bromopropionyl end-capped Pluronic F127 with β-CDs 
at 25 °C. Its number-average molecular weight was 4.47×105 
Da and polydispersity index was 1.07 as determined by GPC. 
The found molar ratio of Pluronic F127 to β-CD to PEGMA 
was 1:21.4:93.1 as measured by 1H NMR. About two thirds 
of β-CDs were found to be still entrapped on the Pluronic 
F127 main chain. However, a substantially higher number of 
PEGMA was incorporated to attach to two ends of the PPR 
most likely due to the fact that the resulting PPR is insoluble 
in aqueous solution and the end-capping ATRP was carried out 
heterogeneously.
F-30-20 was further conjugated with a varying amount of 
DOX. The preparation pathway of the PR-DOX conjugates is 
illustrated in Scheme 1. At first the hydroxyl groups of β-CDs 
entrapped on the Pluronic F127 backbone were activated by 
CDI, followed by reacting with hydrazine hydrate. The products 
were characterized by 1H NMR analysis. As compared with the 
1H NMR spectrum of F-30-20 (Figure 1 (A)), the signals of 
both β-CD and hydrazine moiety were observable in the spec-
trum of PR-HYZ (Figure 1 (B)), and the proton resonance peaks 
of β-CD were heavily broadened. However, the characteristic 
peaks of DOX were not seen in the spectrum of PR-DOX-7 
(Figure 1 (C)) due to the high molecular weight of the PR-
based block copolymer and the trace amount of the DOX in this 
study. In fact, the vibration signals of DOX conjugated onto the 
Sch. 1. Preparation pathway of the PR-DOX conjugates.
Tab. 1. Composition and drug loading content of PR-DOX conjugates
Fig. 1. 1H NMR spectra of (A) unmodified  F-30-20, (B) PR-HYZ 
and (C) PR-DOX-7.
Entry Sample 
Name
Molar composition
(DOX:β-CD)
DOX 
(wt. %)
Feed ratio Found ratioa
1 PR-DOX-2 2:1 1.1:1 4.8
2 PR-DOX-4 4:1 1.5:1 8.3
3 PR-DOX-7 7:1 1.7:1 10.5
a. Determined by UV measurement
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resulting PR sample were observed in the FTIR spectrum. As 
compared to the FTIR spectrum of F-30-20 (Figure 2 (C)), the 
peaks at 535, 567 and 790 cm-1 in the spectrum of PR-DOX-7 
(Figure2 (B)) are attributed to the bending vibrations of C-H 
bondings on the aromatic rings of DOX, and the peaks at 1029 
and 1150 cm-1 are assigned to the characteristic peaks of β-CD. 
It clearly indicated that the DOX was successful conjugated to 
β-CDs entrapped on the Pluronic F127 of the PR-based triblock 
copolymer. Furthermore, the UV-Vis spectroscopy is an appro-
priate analytical method to quantitatively determine the DOX 
content. As shown in Table1, the drug loading content range 
is 4.8-10.5 %, about each β-CD grafted with 1.1-1.7 DOX. 
The PR-DOX-7 sample was used for the following testings.
3.2 Micelle properties of PR-DOX 
in aqueous solution
As can be seen in Figure 3, the PR-DOX-7 conjugates were 
indeed self-assembled into well-defined nano-particles with re-
gard to the micelles of its precursor F-30-20 in aqueous solu-
tion. The diameter of the particles observed is about 300 nm for 
F-30-20 and around 70 nm for the PR-DOX-7 conjugates. The 
diameter shrinkage may be caused by the strong π-π stacking 
between the grafted DOX molecules as well as the flexibility 
of the β-CDs moving along the Pluronic F127 chain, enhancing 
the hydrophobicity of the core in the self-assembly process and 
leading to the nano-particles more compact and smaller.
3.3 Effect of pH on in vitro DOX release rate
The pH sensitivity is crucial for a delivery system to release 
drug at tumor cells (acidic environment) in a controlled man-
ner. Figure 4 depicts the release behavior of DOX from the 
PR-DOX-7 conjugates assessed by UV-Vis spectroscopy in two 
buffered solutions at pH 5.0 and 7.4, respectively. The amount 
of released DOX from the nano-particles incubated at pH 5.0 
and pH 7.4 for the first 12 h was 10 % and 7 % of the total 
drug loaded. After 72 h, however, the release of DOX at pH 5.0 
reached to 37 %, while the release at pH 7.4 was only about 10 %. 
It indicated that the nano-particles self-assembled from the 
PR-DOX conjugates exhibit our desired pH sensitive character. 
Most of the conjugated-DOX can remain in the micelle cores 
for a considerable period of time when the micelles stay in the 
plasma at normal physiological conditions (pH 7.4), while a 
faster release occurs once the micelles are taken by the tumor 
cells because the pH values of the endocytic compartments 
generally ranges from 4.5 to 6.5, much lower than the pH value 
of the normal physiological conditions.
3.4 Cytotoxicity study
Figure 5 (A) illustrates the viability (%) of Hela cells treated 
with F-30-20 and PR-HYZ, respectively. The cells incubated 
with both F-30-20 and PR-HYZ exhibited the viabilities above 
50 % in the concentration range of 0.9-2000 μg/mL, meaning 
the PR-based triblock copolymer and its HYZ derivative have 
nearly no significant toxicity to Hela cells even in a very high 
concentration of 2000 μg/mL. Figure 5 (B) shows the cytotoxic 
effects of free DOX and PR-DOX-7 nano-particles with dif-
ferent DOX concentrations incubated with Hela cells for 72 h. 
The concentration of free DOX required to inhibit cell viability 
by 50 % (IC50) was 1.23 μg/mL. The IC50 of PR-DOX-7 was 
Fig. 2. The FTIR spectra of DOX (A), PR-DOX-7 (B) and F-30-20 (C).
Fig. 3. TEM micrographs of the F-30-20 (A) and PR-DOX-7 (B).
Fig. 4. Release profiles of DOX from the PR-DOX-7 nano-particles at 
different pH values.
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3.7 μg/mL, three-fold more than that of free DOX. The rela-
tively low cytotoxicity of the PR-DOX correlates well with its 
drug delivery process as it is common for the reducing of in 
vitro toxicity of polymer-anticancer drug conjugates as com-
pared to free drug due to the long-term drug release process 
from the nano-particles.
4 Conclusions
In this study, we prepared a PR-based triblock copolymer 
composed of β-CDs being threaded onto Pluronic F127 end-
capped with polymers formed by the in situ ATRP of PEGMA. 
The anticancer drug DOX was conjugated onto the entrapped 
β-CDs via acid-sensitive hydrazone linkage. The resulting 
PR-DOX conjugates enabled to self-assemble into well-defined 
nano-particles with size of around 70 nm in aqueous solution. 
There was only little DOX release at pH=7.4 in the initial peri-
od of time and three-times more DOX released at pH=5.0 over 
a period of longer than 3 days, indicating that the conjugates 
would be stable during blood circulation and in the healthy tis-
sues, but release the loaded DOX in the acid endocytic com-
partments. The assay of anticancer activity in vitro revealed 
that the PR-DOX was effective for inhibiting the growth of the 
Hela cells, while the intact PR-based triblock copolymers pos-
sessed no significant toxicity. This conjugate offers a great po-
tential for intracellular drug delivery into tumor cells in achiev-
ing highly effective and safe drug therapy.
Fig. 5. Cytotoxicity of (A) F-30-20 and PR-HYZ with different polymer concentration, and (B) free DOX and PR-DOX-7 nano-particles with different DOX 
concentrations against Hela cells (incubation time 72 h).
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